EVENTS | VIEW CALENDAR
StemCells Inc., Alan Jacobs, Chief Medical Officer
PALO ALTO, Calif.—StemCells Inc. announced that Dr. Alan Jacobs has joined the company as chief medical officer and vice president of clinical research, neural program.
Formerly the senior director of clinical development at Titan Pharmaceu-ticals, Jacobs offers valuable experience in managing clinical trial development of cell-based therapies for indications such as Parkinson's disease and stroke. In his current capacity, Jacobs will lead the company's adult human neural (brain) stem cell (HuCNS-SC) program through the clinical development process.
At Titan Pharmaceuticals, Jacobs led Titan's Central Nervous System (CNS) clinical development efforts which included Spheramine, a cell-based therapeutic for Parkinson's disease developed in collaboration with Schering AG. He designed and implemented phase II and III clinical studies, managed an ongoing multi-center trial and closely interacted with the Food and Drug Administration.
Jacobs previously served as medical director of Layton Biosciences, where he was responsible for clinical and regulatory development of a neural cell line for the indications of stroke and Parkinson's disease. Jacobs has also worked with neuroscience company Elan Pharmaceu-ticals as assistant director of clinical affairs.
Jacobs received a Ph.D from the University of Pennsylvania, David Mahoney Institute of Neuroscience, and an M.D. from the University of Pennsylvania, School of Medicine, in 1995. Following completion of these programs, Jacobs served as a resident neurosurgeon at the University of California, San Francisco Medical Center.